Vaccinations have begun in a phase I human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis vaccine candidate. Nikki Withers speaks to Dr Daniel Hoft and Christopher Fox about the formulation process and what this means for vaccine development going forward.
List view / Grid view
Infectious Disease Research Institute
26 April 2019 | By European Pharmaceutical Review
As today’s scientists continue to identify new biopharmaceutical products with potential to treat a wide array of diseases, formulation remains the determining factor in their success. But what is involved in these increasingly complex formulation processes and how do they impact the packaging and delivery systems?
24 January 2019 | By Nikki Withers (European Pharmaceutical Review)
A vaccine that does not require a cold chain could be much more easily distributed to communities in need…